RAPID MICRO BIOSYSTEMS, INC.
No enriched coverage for $RPID in the last 7 days.
No SEC Form 4 filings for $RPID in the last 30 days.
See all $RPID insider activity →Rapid Micro Biosystems (RPID) reported Q2 2026 revenue of $8.1M, up 10.9% YoY, with product revenue $5.3M and service revenue $2.8M. Recurring revenue was $5.0M, up 14.3% YoY, and gross margin was 15.0%. Net loss was $12.9M ($0.27/share). Full-year revenue guidance was reaffirmed at $37M to $41M.
Rapid Micro Biosystems (NASDAQ: RPID) reported Q2 margin improvements, with consumables margins up 17 points YoY and service margin at a record 49%. Operating expenses rose to $13.5M. Net loss was $12.9M ($0.27/share). The company reaffirmed 2026 revenue guidance of $37M-$41M, raised validation targets, and projected Q3 revenue at least $9.5M.
Rapid Micro Biosystems (Nasdaq: RPID) reported Q2 2026 total revenue of $8.1 million, up 11% year over year. Recurring revenue rose 14% to $5.0 million, 63% of total. Gross margin was a record 15%. The company reaffirmed 2026 revenue guidance of $37.0 million to $41.0 million and gross margin near 20%, and raised validation guidance to at least 27.
Recent RPID coverage spans financial news and earnings.
Guidance reaffirmation plus margin and recurring revenue growth supports a constructive near-term earnings trajectory, but cash burn and working-capital timing remain key risks.
Guidance and margin/validation targets suggest improving operating leverage, but cash burn and non-recurring expenses keep downside risk.
Q2 results show improving gross margin and steady recurring growth, with guidance reaffirmed and validation targets raised.
Q2 results show improving gross margin and continued recurring revenue growth, while guidance and validation targets set near-term expectations for FY2026 execution.
Inducement equity grant is a routine corporate action; it may slightly affect dilution/overhang but is unlikely to move the stock materially by itself.
alphai scores every news story that mentions RPID with an AI model for sentiment and relevance, and aggregates insider trades from RAPID MICRO BIOSYSTEMS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Rapid Micro Biosystems (RPID) reported Q2 2026 revenue of $8.1M, up 10.9% YoY, with product revenue $5.3M and service revenue $2.8M. Recurring revenue was $5.0M, up 14.3% YoY, and gross margin was 15.0%. Net loss was $12.9M ($0.27/share). Full-year revenue guidance was reaffirmed at $37M to $41M.
6 min readRapid Micro Biosystems (NASDAQ: RPID) reported Q2 margin improvements, with consumables margins up 17 points YoY and service margin at a record 49%. Operating expenses rose to $13.5M. Net loss was $12.9M ($0.27/share). The company reaffirmed 2026 revenue guidance of $37M-$41M, raised validation targets, and projected Q3 revenue at least $9.5M.
4 min readRapid Micro Biosystems (Nasdaq: RPID) reported Q2 2026 total revenue of $8.1 million, up 11% year over year. Recurring revenue rose 14% to $5.0 million, 63% of total. Gross margin was a record 15%. The company reaffirmed 2026 revenue guidance of $37.0 million to $41.0 million and gross margin near 20%, and raised validation guidance to at least 27.
7 min readRAPID MICRO BIOSYSTEMS, INC. (RPID) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapid Micro Biosystems Reports Second Quarter 2026 Financial Results • Reports second quarter 2026 total revenue of $8.1 million, representing 11% growth compared to the second quarter of 2025 ◦ Achieved a significant milestone with the 200th Growth Direct system pla
6 min readRapid Micro Biosystems (Nasdaq: RPID) said June 3, 2026 it granted 60,000 restricted stock units to a new employee as an inducement under Nasdaq Listing Rule 5635(c)(4). The award was approved by independent directors and will vest one-third annually over three years, subject to continued employment.
2 min readRapid Micro Biosystems (NASDAQ:RPID) experienced an 18.9% increase in short interest, reaching 377,502 shares as of March 31st, indicating a 1.4 days-to-cover ratio. This occurred despite recent insider selling by the COO and CFO, who disposed of shares worth over $73,000 in March. The company also reported missing EPS estimates but exceeded revenue expectations for the last quarter, with a current market capitalization of approximately $103.7 million.
3 min readRapid Micro Biosystems (RPID) announced inducement equity awards to three new employees on February 2, 2026. The awards include 205,000 Restricted Stock Units (RSUs) and 168,000 stock options, with options priced at $4.19 per share. These grants were approved by independent directors in compliance with Nasdaq Listing Rule 5635(c)(4) and are subject to time-based vesting schedules.
2 min readLEXINGTON, Mass., Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Rapid Micro Biosystems, Inc. ( Nasdaq: RPID ) ( the "Company" ) , an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare ...
2 min readLEXINGTON, Mass., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) ( the "Company" ) , an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare ...
2 min readLEXINGTON, Mass., Oct. 30, 2025 ( GLOBE NEWSWIRE ) -- Rapid Micro Biosystems, Inc. ( Nasdaq: RPID ) ( the "Company" ) , an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare ...
3 min read
